Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was upgraded by Zacks Investment Research from a “sell” rating to a “strong-buy” rating in a research note issued on Tuesday. The firm presently has a $18.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 12.15% from the company’s current price.

According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

VNDA has been the topic of several other research reports. Jefferies Group LLC reissued a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. started coverage on Vanda Pharmaceuticals in a report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price target on the stock. TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $23.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average target price of $21.33.

Shares of Vanda Pharmaceuticals (VNDA) traded down 1.25% during trading on Tuesday, hitting $15.85. The stock had a trading volume of 163,572 shares. The stock’s market cap is $708.78 million. The company’s 50 day moving average price is $15.89 and its 200 day moving average price is $14.60. Vanda Pharmaceuticals has a 12 month low of $11.58 and a 12 month high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.88% and a negative net margin of 6.54%. The firm had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same quarter in the prior year, the company earned $0.01 EPS. Vanda Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. Equities research analysts expect that Vanda Pharmaceuticals will post ($0.61) earnings per share for the current fiscal year.

WARNING: “Zacks Investment Research Upgrades Vanda Pharmaceuticals Inc. (VNDA) to Strong-Buy” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/08/zacks-investment-research-upgrades-vanda-pharmaceuticals-inc-vnda-to-strong-buy.html.

Large investors have recently modified their holdings of the company. Legal & General Group Plc increased its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $193,000. Capital Fund Management S.A. acquired a new position in Vanda Pharmaceuticals during the first quarter worth approximately $195,000. Dynamic Technology Lab Private Ltd acquired a new position in Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Finally, AQR Capital Management LLC acquired a new position in Vanda Pharmaceuticals during the fourth quarter worth approximately $223,000. Institutional investors own 91.42% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.